EP3679053A4 - CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE - Google Patents

CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE Download PDF

Info

Publication number
EP3679053A4
EP3679053A4 EP18852912.7A EP18852912A EP3679053A4 EP 3679053 A4 EP3679053 A4 EP 3679053A4 EP 18852912 A EP18852912 A EP 18852912A EP 3679053 A4 EP3679053 A4 EP 3679053A4
Authority
EP
European Patent Office
Prior art keywords
affair
highly
selective binding
binding conjugate
cxcr4 selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18852912.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3679053A1 (en
Inventor
Junge ZHANG
Liang Zeng Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mainline Biosciences Inc
Original Assignee
Mainline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mainline Biosciences Inc filed Critical Mainline Biosciences Inc
Publication of EP3679053A1 publication Critical patent/EP3679053A1/en
Publication of EP3679053A4 publication Critical patent/EP3679053A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18852912.7A 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE Withdrawn EP3679053A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554354P 2017-09-05 2017-09-05
PCT/US2018/018530 WO2019050564A1 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USING THE SAME

Publications (2)

Publication Number Publication Date
EP3679053A1 EP3679053A1 (en) 2020-07-15
EP3679053A4 true EP3679053A4 (en) 2021-10-27

Family

ID=65635072

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18852912.7A Withdrawn EP3679053A4 (en) 2017-09-05 2018-02-17 CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE

Country Status (6)

Country Link
EP (1) EP3679053A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020532496A (cg-RX-API-DMAC10.html)
KR (2) KR20230145543A (cg-RX-API-DMAC10.html)
CN (1) CN111183146A (cg-RX-API-DMAC10.html)
CA (1) CA3065086A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019050564A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123437B2 (en) 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
EP3956346A4 (en) * 2019-04-18 2023-01-18 Provincial Health Services Authority NEW RADIOLABALED DIAGNOSTIC AND THERAPEUTIC COMPOUNDS TARGETING CXCR4
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
WO2022082312A1 (en) 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
EP4321526A4 (en) 2022-02-11 2026-04-15 C Biomex Co Ltd Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
EP4511384A4 (en) * 2022-04-20 2026-07-29 Provincial Health Services Authority Compounds targeting CXCR4, and their manufacturing and use processes
CN116023438B (zh) * 2023-02-06 2025-07-11 中国药科大学 一种cxcr4靶向多肽及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
US20130079292A1 (en) * 2010-01-26 2013-03-28 Consiglio Nazionale Delle Ricerche Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses
US20150050351A1 (en) * 2013-01-02 2015-02-19 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.
US20150218219A1 (en) * 2012-06-06 2015-08-06 Polyphor Ag Beta-hairpin peptidomimetics
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
WO2008150689A1 (en) * 2007-05-30 2008-12-11 Eli Lilly And Company Cyclic peptide cxcr4 antagonists
US20130079292A1 (en) * 2010-01-26 2013-03-28 Consiglio Nazionale Delle Ricerche Cyclic peptides binding cxcr4 receptor and relative medical and diagnostic uses
CN102626522A (zh) * 2012-04-12 2012-08-08 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
US20150218219A1 (en) * 2012-06-06 2015-08-06 Polyphor Ag Beta-hairpin peptidomimetics
US20150050351A1 (en) * 2013-01-02 2015-02-19 Lucia Irene Gonzalez Stereoisomer peptides, their polymer conjugates, their encapsulation into nanoparticles, and uses thereof for the treatment of diseases caused by abnormal angiogenesis.
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PENG SHENG-BIN ET AL: "Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 2, 1 February 2015 (2015-02-01), pages 480 - 490, XP002771606, ISSN: 1538-8514, DOI: 10.1158/1535-7163.MCT-14-0850 *
YAN WANG ET AL: "Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery", CURRENT PHARMACOLOGY REPORTS, vol. 2, no. 1, 4 January 2016 (2016-01-04), pages 1 - 10, XP055747815, DOI: 10.1007/s40495-015-0044-8 *
YASUSHI YOSHIKAWA ET AL: "Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4FC131 interactions", BIORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 22, no. 6, 31 January 2012 (2012-01-31), pages 2146 - 2150, XP028402827, ISSN: 0960-894X, [retrieved on 20120208], DOI: 10.1016/J.BMCL.2012.01.134 *

Also Published As

Publication number Publication date
WO2019050564A1 (en) 2019-03-14
EP3679053A1 (en) 2020-07-15
CN111183146A (zh) 2020-05-19
JP2020532496A (ja) 2020-11-12
KR20230145543A (ko) 2023-10-17
KR20200043970A (ko) 2020-04-28
CA3065086A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
EP4008728C0 (en) CD70 BINDING MOLECULES AND THEIR METHODS OF USE
EP3704254A4 (en) CAS12C COMPOSITIONS AND METHOD OF USE
EP3714845A4 (en) BYPASS CATHETER TO IMPROVE ITS LOCATION AS WELL AS CATHETER
EP3618896A4 (en) INJECTION APPARATUS AND METHOD OF USE
EP3691677A4 (en) COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE
EP3526256C0 (en) ANTI-LAG-3 ANTIBODIES AND METHODS OF USE THEREOF
EP3538561A4 (en) RNA-GUIDED VARIANT POLYPEPTIDES AND THEIR METHODS OF USE
EP3310378C0 (en) ANTI-C1 ANTIBODIES AND METHODS OF USE THEREOF
EP3538152A4 (en) ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
EP3313404C0 (en) THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE
EP3596960A4 (en) Precise positioning system and method of using the same
EP3436036A4 (en) BCMA BINDING MOLECULES AND METHODS OF USE THEREOF
EP3970680C0 (en) MEDICAL TECHNOLOGY STATION AND METHOD OF USE
EP3668006C0 (en) METHOD FOR DEFINITING PDU TYPE AND ASSOCIATED ENTITIES
EP3720378C0 (en) CATHETER AND METHOD OF ASSEMBLING CATHETER
EP3595699A4 (en) PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
EP3478723A4 (en) PD-L1 SPECIFIC ANTIBODIES AND METHODS FOR USING THEM
EP3538123A4 (en) ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
EP3585426A4 (en) COMPOSITIONS AND METHODS OF TUMOR TRANSDUCTION
EP3723763A4 (en) ANTI-CD22-MAYTANSIN ANTIBODY CONJUGATES, RELATED COMBINATIONS AND METHODS OF USE
EP3640333A4 (en) GENE EDITING SYSTEM AND GENE EDITING METHOD
EP3565828A4 (en) SIRP1 ALPHA-41BBL FUSION PROTEIN AND PROCESSES FOR USE
EP3922649C0 (en) ANTI-HTRA1 ANTIBODIES AND METHODS OF USE THEREOF
EP3634237A4 (en) A tomographic imaging system and process
EP3600372A4 (en) SYNTHEKIN COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 7/06 20060101AFI20210621BHEP

Ipc: C07K 7/50 20060101ALI20210621BHEP

Ipc: C07K 5/12 20060101ALI20210621BHEP

Ipc: A61K 38/00 20060101ALI20210621BHEP

Ipc: A61K 49/00 20060101ALI20210621BHEP

Ipc: C07K 14/705 20060101ALI20210621BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210927

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/705 20060101ALI20210921BHEP

Ipc: A61K 49/00 20060101ALI20210921BHEP

Ipc: A61K 38/00 20060101ALI20210921BHEP

Ipc: C07K 5/12 20060101ALI20210921BHEP

Ipc: C07K 7/50 20060101ALI20210921BHEP

Ipc: C07K 7/06 20060101AFI20210921BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240716